当前位置: 首页 > 详情页

A Review on the Effect of Traditional Chinese Medicine Against Anthracycline-Induced Cardiac Toxicity

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [1]Guang’anmen Hospital, Chinese Academy of Chinese Medical Sciences, Beijing, China, [2]Key Laboratory of Chinese Internal Medicine of the Ministry of Education, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China, [3]Department of Cardiology, Beijing Anzhen Hospital of the Capital University of Medical Sciences, Beijing, China, [4]Department of Pharmacology, School of Pharmaceutical Sciences, South-Central University for Nationalities, Wuhan, China, [5]Department of Pancreatic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
出处:
ISSN:

关键词: anthracyclines traditional Chinese medicine cardiac toxicity adverse effects antineoplastic

摘要:
Anthracyclines are effective agents generally used to treat solid-tumor and hematologic malignancies. The use of anthracyclines for over 40 years has improved cancer survival statistics. Nevertheless, the clinical utility of anthracyclines is limited by its dose-dependent cardiotoxicity that adversely affects 10-30% of patients. Anthracycline-induced cardiotoxicity may be classified as acute/subacute or chronic/late toxicity and leads to devastating adverse effects resulting in poor quality of life, morbidity, and premature mortality. Traditional Chinese medicine has a history of over 2,000 years, involving both unique theories and substantial experience. Several studies have investigated the potential of natural products to decrease the cardiotoxic effects of chemotherapeutic agents on healthy cells, without negatively affecting their antineoplastic activity. This article discusses the mechanism of anthracycline-induced cardiotoxicity, and summarizes traditional Chinese medicine treatment for anthracycline-induced heart failure (HF), cardiac arrhythmia, cardiomyopathy, and myocardial ischemia in recent years, in order to provide a reference for the clinical prevention and treatment of cardiac toxicity.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类 | 2 区 医学
小类 | 2 区 药学
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 药学
JCR分区:
出版当年[2016]版:
Q1 PHARMACOLOGY & PHARMACY
最新[2024]版:
Q1 PHARMACOLOGY & PHARMACY

影响因子: 最新[2024版] 最新五年平均 出版当年[2016版] 出版当年五年平均 出版前一年[2015版] 出版后一年[2017版]

第一作者:
第一作者机构: [1]Guang’anmen Hospital, Chinese Academy of Chinese Medical Sciences, Beijing, China, [2]Key Laboratory of Chinese Internal Medicine of the Ministry of Education, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China,
共同第一作者:
通讯作者:
通讯机构: [1]Guang’anmen Hospital, Chinese Academy of Chinese Medical Sciences, Beijing, China, [2]Key Laboratory of Chinese Internal Medicine of the Ministry of Education, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China, [5]Department of Pancreatic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:17708 今日访问量:0 总访问量:943 更新日期:2025-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院